Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Baxter
Merck
Johnson and Johnson
Moodys

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for AZD5718


Email this page to a colleague

« Back to Dashboard

What is the drug development status for AZD5718?

AZD5718 is an investigational drug.

There have been 12 clinical trials for AZD5718. The most recent clinical trial was a Phase 2 trial, which was initiated on October 30th 2017.

The most common disease conditions in clinical trials are Coronary Artery Disease, Myocardial Ischemia, and Coronary Disease. The leading clinical trial sponsors are AstraZeneca, Parexel, and Quotient Sciences.

There are three US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for AZD5718
TitleSponsorPhase
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy VolunteersParexelPhase 1
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy VolunteersAstraZenecaPhase 1
PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromEAstraZenecaPhase 2

See all AZD5718 clinical trials

Clinical Trial Summary for AZD5718

Top disease conditions for AZD5718
Top clinical trial sponsors for AZD5718

See all AZD5718 clinical trials

US Patents for AZD5718

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD5718 ⤷  Try it Free Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Try it Free
AZD5718 ⤷  Try it Free Pyrazole derivatives useful as 5-lipdxygenase activating protein (FLAP) inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Try it Free
AZD5718 ⤷  Try it Free Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahyd- ropyrazolo[1,5-A]pyrazin-3-yl)cyclohexanecarboxamide AstraZeneca AB (Sodertalje, SE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD5718

Drugname Country Document Number Estimated Expiration Related US Patent
AZD5718 Argentina AR104512 2035-05-04 ⤷  Try it Free
AZD5718 Australia AU2016258874 2035-05-04 ⤷  Try it Free
AZD5718 Brazil BR112017022757 2035-05-04 ⤷  Try it Free
AZD5718 Canada CA2983668 2035-05-04 ⤷  Try it Free
AZD5718 Chile CL2017002660 2035-05-04 ⤷  Try it Free
AZD5718 China CN107646036 2035-05-04 ⤷  Try it Free
AZD5718 Colombia CO2017011506 2035-05-04 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Baxter
Merck
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.